Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis
Science Advances · 2025
DOI: 10.1126/sciadv.ady4135 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Endong Zhang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Myeloid-Derived Suppressor Cells, Multiple Sclerosis, Nanoparticles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Massive immune cell infiltration and persistent inflammation in the central nervous system (CNS) are key hallmarks of multiple sclerosis. Here, we report a myeloid-derived suppressor cell (MDSC)–based therapeutic strategy, named CNS Immune Targeting Enabled by MDSCs (CITED), which uses surface-decorated MDSCs carrying rapamycin nanoparticles (NPs) for targeted multimodal immune reprogramming in CNS. We show that NP decoration enhances MDSC immunomodulatory function, facilitates their trafficking to inflamed CNS regions, and increases NP accumulation within CNS. In an experimental autoimmune encephalomyelitis model, CITED exhibited robust therapeutic efficacy, resulting in reduced disease progression, improved motor function, and diminished myelin damage. Mechanistic studies reveal that CITED exerts its therapeutic effects by targeted reprogramming of both innate and adaptive immune responses in CNS. Specifically, CITED inhibits immune cell infiltration, rebalances CD4 T cell phenotypes, and promotes the polarization of myeloid cells toward anti-inflammatory phenotypes. Collectively, CITED could provide a broadly effective approach for targeted immune restoration in multiple sclerosis and potentially other autoimmune diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Illinois Chicago, Chicago, IL, USA.
- Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois, Chicago, IL, USA.
- University of Illinois Cancer Center, Chicago, IL, USA.
ORCID-Profile: Endong Zhang, Chih-Jia Chao, Shan He, Qing Bao, Dahee Jung, Shubhi Srivastava, Edidiong Udofa, Philana Phan, Steve Seung-Young Lee, Jalees Rehman, Zongmin Zhao
Förderung
- NIA NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Zhang, E., Algarni, H., Zhang, L., Chao, C. J., He, S., Upadhye, A., Bao, Q., Jung, D., Srivastava, S., Udofa, E., Phan, P., Nikolic, D. S., Lee, S. S., Rehman, J., & Zhao, Z. (2025). Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis. Science Advances. https://doi.org/10.1126/sciadv.ady4135
Vancouver
Zhang E, Algarni H, Zhang L, Chao CJ, He S, Upadhye A, et al. Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis. Science Advances. 2025. doi:10.1126/sciadv.ady4135
BibTeX
@article{Zhang2025,
author = {Zhang, Endong and Algarni, Hanan and Zhang, Luyu and Chao, Chih-Jia and He, Shan and Upadhye, Aditi and Bao, Qing and Jung, Dahee and Srivastava, Shubhi and Udofa, Edidiong and Phan, Philana and Nikolic, Dejan S and Lee, Steve Seung-Young and Rehman, Jalees and Zhao, Zongmin},
title = {Nanoparticle-boosted myeloid-derived suppressor cell therapy for immune reprogramming in multiple sclerosis},
journal = {Science Advances},
year = {2025},
doi = {10.1126/sciadv.ady4135}
}
EUVIMED